Gilead Sciences (GILD): CFO sold ~$14.1M
Andrew D Dickinson, CFO at Gilead Sciences, sold ~$14.1M of Gilead Sciences shares.
- ~$14.1M
- Approx. value · 138K sh @ $102.22
- 171K
- Holds after · shares reported
- Traded
- Feb 12, 2025
- Filed
- Feb 14, 2025
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- Dec 16, 2024InsiderCFO sold ~$782K of GILD shares in the open market
- Dec 24, 2024CongressDisclosed purchase of GILD — reported range $1,001 - $15,000
- Jan 15, 2025InsiderCFO sold ~$228K of GILD shares in the open market
- Jan 31, 2025InsiderCFO sold ~$13.8M of GILD shares in the open market
- Feb 12, 2025 · this disclosureInsiderCFO sold ~$14.1M of GILD shares in the open market
What came next
- Feb 18, 2025InsiderCFO sold ~$260K of GILD shares in the open market
- Feb 19, 2025FDAFDA drug approval: Odefsey
- Feb 19, 2025FDAFDA drug approval: Odefsey
- Mar 7, 2025FDARecall: Sofosbuvir and Velpatasvir, 400 mg/100 mg tablets, 28 tablets: 2x14 blister cards, Rx Only, Manufactured for: Asegua Therapeutics LLC an affiliate of Gilead Sc…
- Mar 7, 2025CongressDisclosed purchase of GILD — reported range $1,001 - $15,000
- Mar 10, 2025Insider · 1 personInsiders: 2 sales (~$2.1M)
- Mar 10, 2025CongressDisclosed purchase of GILD — reported range $1,001 - $15,000
- Mar 17, 2025InsiderCFO sold ~$276K of GILD shares in the open market
- Mar 31, 2025CongressDisclosed purchase of GILD — reported range $15,001 - $50,000
- Apr 15, 2025InsiderCFO sold ~$266K of GILD shares in the open market
- Apr 16, 2025CongressDisclosed sale of GILD — reported range $1,001 - $15,000
- May 5, 2025Congress · 1 personMembers of Congress: 3 purchases
- May 14, 2025CongressDisclosed sale of GILD — reported range $1,001 - $15,000
- May 15, 2025InsiderCFO sold ~$250K of GILD shares in the open market
- May 22, 2025Insider · 1 personInsiders: 3 sales (~$3.0M)
- May 30, 2025Insider · 1 personInsiders: 2 sales (~$1.1M)
How to read SEC Form 4
Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.
Full guide: What is an SEC Form 4?
What else is on file for Gilead Sciences
For Gilead Sciences, OQRO holds 47 insider filings (SEC Form 4 or Form 144) and 1 fund holdings report (13F) dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its GILD page.
Other recent filings by Andrew D Dickinson, Chief Financial Officer
- SEC Form 4 at Gilead Sciences (GILD)Nov 18, 2026
- SEC Form 4 at Gilead Sciences (GILD)Oct 16, 2026
- SEC Form 4 at Gilead Sciences (GILD)Sep 16, 2026
- SEC Form 4 at Gilead Sciences (GILD)Aug 18, 2026
- SEC Form 4 at Gilead Sciences (GILD)Jul 16, 2026
The full history of Andrew D Dickinson, Chief Financial Officer is on the profile page.
How this filing works
Explore the data
Common questions
Which Gilead Sciences (GILD) insider traded, and how much?
Andrew D Dickinson, CFO at Gilead Sciences, sold ~$14.1M of Gilead Sciences shares. 138K shares at $102.22.
When did it happen, and when was it made public?
Traded: Feb 12, 2025. Filed: Feb 14, 2025. That is 2 days between the two dates.
Is the dollar amount exact?
It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.
Where does this information come from?
From the SEC Form 4, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.
What else has been disclosed about Gilead Sciences recently?
For Gilead Sciences, OQRO holds 47 insider filings (SEC Form 4 or Form 144) and 1 fund holdings report (13F) dated in the last 90 days. They are listed on the GILD page.
Does this mean GILD stock is a buy or a sell?
No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.
Is OQRO free?
Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.
Other disclosures at Gilead Sciences
- SEC Form 4Nov 18, 2026
- SEC Form 4Nov 18, 2026
- SEC Form 4Nov 18, 2026
- SEC Form 4Nov 18, 2026
- SEC Form 13F-HRNov 16, 2026
- SEC Form 144Nov 16, 2026
Everything OQRO holds on this company is on its GILD page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO is free for everyone. No card, no trial
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data
